Correcção da anemia dos doentes insuficientes renais crónicos em hemodiálise com eritropoietina recombinante humana: experiência de 12 meses.
In this study we analyse the effects of the administration of recombinant human erythropoietin (rHuEpo) during 12 months to correct the anaemia in a group of 17 patients (9 men and 8 women; mean age 52.7 +/- 13.7; range 23 to 68 years) with end-stage renal disease (ESRD) on chronic haemodialysis (HD...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ordem dos Médicos
1990-12-01
|
| Series: | Acta Médica Portuguesa |
| Online Access: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4596 |
| _version_ | 1828132608097124352 |
|---|---|
| author | F T de Sousa M M Prata J V Barbas J P dos Santos |
| author_facet | F T de Sousa M M Prata J V Barbas J P dos Santos |
| author_sort | F T de Sousa |
| collection | DOAJ |
| description | In this study we analyse the effects of the administration of recombinant human erythropoietin (rHuEpo) during 12 months to correct the anaemia in a group of 17 patients (9 men and 8 women; mean age 52.7 +/- 13.7; range 23 to 68 years) with end-stage renal disease (ESRD) on chronic haemodialysis (HD) for a range of 14 to 126 months (mean 43.1 +/- 29.6). In the correction period the rHuEpo was started at 50 U/Kg i.v. 3 times a week, immediately after each HD. This dose was maintained during 4 weeks and then increased in 25 U/Kg steps until haemoglobin (Hb) levels of 12 g/dl or a maximum dose of 100 U/Kg were reached. During the long-term maintenance period the individual rHuEpo dose was adjusted to keep the Hb constant at the target level of 10-12 g/dl. Baseline blood tests were done before the beginning of the treatment and every months afterwards. The levels of Hb increased significantly in week 4 and at the end of the first 3 month only 4 patients had no answer to rHuEpo. These patients had baseline serum ferritin levels below 100 ng/ml and responded well when this defficiency was corrected with oral iron. When levels of 30-35 vol% haematocrit (Hct) were reached the dose of rHuEpo could be reduced (150 to 200 U/Kg/week). The serum ferritin levels decreased 51% from a mean baseline level of 247.8 +/- 196 to 121.1 +/- 154.9 ng/ml with the onset of the maintenance phase (p less than 0.05). |
| first_indexed | 2024-04-11T17:07:25Z |
| format | Article |
| id | doaj.art-dfb8c45222b84369bfd8158dd79551cf |
| institution | Directory Open Access Journal |
| issn | 0870-399X 1646-0758 |
| language | English |
| last_indexed | 2024-04-11T17:07:25Z |
| publishDate | 1990-12-01 |
| publisher | Ordem dos Médicos |
| record_format | Article |
| series | Acta Médica Portuguesa |
| spelling | doaj.art-dfb8c45222b84369bfd8158dd79551cf2022-12-22T04:13:00ZengOrdem dos MédicosActa Médica Portuguesa0870-399X1646-07581990-12-013610.20344/amp.4596Correcção da anemia dos doentes insuficientes renais crónicos em hemodiálise com eritropoietina recombinante humana: experiência de 12 meses.F T de Sousa0M M PrataJ V BarbasJ P dos SantosDepartamento de Nefrologia, Hospital de Santa Maria, Lisboa.In this study we analyse the effects of the administration of recombinant human erythropoietin (rHuEpo) during 12 months to correct the anaemia in a group of 17 patients (9 men and 8 women; mean age 52.7 +/- 13.7; range 23 to 68 years) with end-stage renal disease (ESRD) on chronic haemodialysis (HD) for a range of 14 to 126 months (mean 43.1 +/- 29.6). In the correction period the rHuEpo was started at 50 U/Kg i.v. 3 times a week, immediately after each HD. This dose was maintained during 4 weeks and then increased in 25 U/Kg steps until haemoglobin (Hb) levels of 12 g/dl or a maximum dose of 100 U/Kg were reached. During the long-term maintenance period the individual rHuEpo dose was adjusted to keep the Hb constant at the target level of 10-12 g/dl. Baseline blood tests were done before the beginning of the treatment and every months afterwards. The levels of Hb increased significantly in week 4 and at the end of the first 3 month only 4 patients had no answer to rHuEpo. These patients had baseline serum ferritin levels below 100 ng/ml and responded well when this defficiency was corrected with oral iron. When levels of 30-35 vol% haematocrit (Hct) were reached the dose of rHuEpo could be reduced (150 to 200 U/Kg/week). The serum ferritin levels decreased 51% from a mean baseline level of 247.8 +/- 196 to 121.1 +/- 154.9 ng/ml with the onset of the maintenance phase (p less than 0.05).https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4596 |
| spellingShingle | F T de Sousa M M Prata J V Barbas J P dos Santos Correcção da anemia dos doentes insuficientes renais crónicos em hemodiálise com eritropoietina recombinante humana: experiência de 12 meses. Acta Médica Portuguesa |
| title | Correcção da anemia dos doentes insuficientes renais crónicos em hemodiálise com eritropoietina recombinante humana: experiência de 12 meses. |
| title_full | Correcção da anemia dos doentes insuficientes renais crónicos em hemodiálise com eritropoietina recombinante humana: experiência de 12 meses. |
| title_fullStr | Correcção da anemia dos doentes insuficientes renais crónicos em hemodiálise com eritropoietina recombinante humana: experiência de 12 meses. |
| title_full_unstemmed | Correcção da anemia dos doentes insuficientes renais crónicos em hemodiálise com eritropoietina recombinante humana: experiência de 12 meses. |
| title_short | Correcção da anemia dos doentes insuficientes renais crónicos em hemodiálise com eritropoietina recombinante humana: experiência de 12 meses. |
| title_sort | correccao da anemia dos doentes insuficientes renais cronicos em hemodialise com eritropoietina recombinante humana experiencia de 12 meses |
| url | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4596 |
| work_keys_str_mv | AT ftdesousa correccaodaanemiadosdoentesinsuficientesrenaiscronicosemhemodialisecomeritropoietinarecombinantehumanaexperienciade12meses AT mmprata correccaodaanemiadosdoentesinsuficientesrenaiscronicosemhemodialisecomeritropoietinarecombinantehumanaexperienciade12meses AT jvbarbas correccaodaanemiadosdoentesinsuficientesrenaiscronicosemhemodialisecomeritropoietinarecombinantehumanaexperienciade12meses AT jpdossantos correccaodaanemiadosdoentesinsuficientesrenaiscronicosemhemodialisecomeritropoietinarecombinantehumanaexperienciade12meses |